MedTrace Logo

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

NCT05019040 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-01-31

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of multiple ascending dose (MAD) of PA1010 tablets in Chinese adults with Chronic Hepatitis B.

Conditions

  • Chronic HBV Infection

Interventions

DRUG

PA1010

TDF as control

Sponsors & Collaborators

  • Zhejiang Palo Alto Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Lai Wei, MD · Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2022-11-15
Completion
2022-11-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019040 on ClinicalTrials.gov